Editas Medicine Inc. (EDIT) shows monthly volitility of 9.58%


Editas Medicine Inc. (EDIT) reported its last quarter results on 03/07/2017. This Company belongs to Medical sector.

In the last trading session, The Company traded 6.6 Million shares. The Stock Market opened sessions at 22.8 and closed at 22.3. There was a stock decrease by -10.48 percent.

According to Yahoo Finance, the price target for the company which analysts are aiming is 40. The 1-year price target of the company is 33.5.

Investors expected a price target of -0.63 for this quarter.  Zacks Investment Research gave Editas Medicine Inc. (EDIT) a rating of 1.8 on a scale of 1 to 5. Here, 1 indicates a Strong Buy and 5 indicates a Strong Sell.

Considering the performance, Editas Medicine Inc. (EDIT)’s shares have the potential to reach a high EPS of -0.65 per share, and a low EPS of -0.77 per share in the current quarter. All of these Earnings estimates are a consensus recommendation of 4 Analysts. According to them, the median (average) EPS the company could deliver is -0.69/share. While the actual EPS the company reported in the same quarter previous year was -0.8/share.

For the quarter ending 11/07/2016, The Analyst projected that the company could deliver EPS of -0.64 while the company provided its Actual EPS of -0.59 showing a difference of 0.05 Percent between the Estimated and Actual EPS. Hence, the surprise factor was 7.8 percent.

Analysts estimated $-0.62/share for the previous Quarter, where Editas Medicine Inc. (EDIT) reported Actual EPS of $-1.1/share with the difference of -0.48 percent and a surprise of -77.4 percent.

The 4 analysts offering 12-month price forecasts for Editas Medicine Inc have a median target of 33.50, with a high estimate of 40.00 and a low estimate of 27.00. The median estimate represents a +50.22% increase from the last price of 22.30.

For the current quarter, the highest estimate analysts provided is 2.2 Million and the lowest is 900 Million. These 4 Analysts are also projecting the mean revenue estimate of 1.28 Million. The year ago sales the company reported in the same quarter is 805 Million.

While Looking at Sales Growth (Year/est), the company is currently showing a percentage value of 5.6 percent.

Editas Medicine Inc. (EDIT) topped its 52-week high price target of 43.5 on Apr 6, 2016. The company reached a 52-week low at 12.43 on Nov 3, 2016.

The company’s stock currently has 818.86 Million in market capitalization. The volatility rate is 9.12% percent and 9.58% percent each. Price per earning (ttm) stands at 0.

Company Profile:

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.